secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2026-08-03T20:14:27+00:00
Accession:  0001628280-26-051852
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q2 revenue $114.4M, exome/genome volume up 32% YoY; reiterates FY guidance
--------------------------------------------------------------------------------

- Q2 revenue $114.4M (+11% YoY); exome/genome revenue $100.3M (+17% YoY).
- Exome/genome volume 30,785 (+32% YoY); adjusted gross margin 70% (GAAP 68%).
- Adjusted net income $0.4M (up $8.6M from Q1); GAAP net loss $17.7M.
- Reiterates FY2026 revenue guidance $475-490M with exome/genome volume growth at least 30%.
- Amended Blackstone loan: additional $50M term loan (total $150M); Blackstone bought $5M stock at $61/share; pro forma cash ~$188M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/0001628280-26-051852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/wgs-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-051852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer